Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation

APPROVED_FOR_MARKETING

Conditions studied: Advanced Cancer, Metastatic Cancer, Malignant Neoplasm

In brief

The objective of this EAP is to provide expanded access of adagrasib (MRTX849) to patients with previously treated advanced solid tumors harboring a KRAS G12C mutation.

Key facts

Study ID

NCT05162443

Run by

Bristol-Myers Squibb

Last updated by the study team

2025-08-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed diagnosis of an advanced/metastatic solid tumor
• Confirmed presence of a KRASG12C mutation
• Ineligible for an ongoing clinical trial of MRTX849
• No available or not eligible for standard of care treatment
• Adequate organ function
• CNS Metastases (within set parameters) are allowed
• ECOG performance status of ≤ 2

You may not qualify if…

• History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of MRTX849 treatment or result in inability to swallow
• Prior therapy targeting a KRAS G12C mutation
• Other active cancer

Where it is running

• California Pacific Medical Center — San Francisco, California, United States
• Providence Medical Group Santa Rosa - Cancer Center — Santa Rosa, California, United States
• Hartford Hospital — Hartford, Connecticut, United States
• Piedmont Cancer Institute — Atlanta, Georgia, United States
• Mayo Clinic - Rochester — Rochester, Minnesota, United States
• Renown Health — Reno, Nevada, United States
• Lehigh Valley Cancer Institute — Allentown, Pennsylvania, United States
• Lumi Research — Kingwood, Texas, United States
• Virginia Cancer Institute — Richmond, Virginia, United States
• Seattle Integrative Cancer Center — Renton, Washington, United States
• Swedish Cancer Institute — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.